Thromboxane synthase deficiency improves insulin action and attenuates adipose tissue fibrosis

American Journal of Physiology - Endocrinology and Metabolism

Volumn 308, Issue 9, 2015, Pages E792-E804

  Lei, Xia ^a   Li, Qing ^a,b   Rodriguez, Susana ^a   Tan, Stefanie Y ^a   Seldin, Marcus M ^a   McLenithan, John C ^c   Jia, Weiping ^b   Wong, G William ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Adipose tissue; C1q tumor necrosis factor related protein; Diabetes; Eicosanoid; Fibrosis; Obesity; Thromboxane

Indexed keywords

ADIPONECTIN; COMPLEMENT COMPONENT C1Q TUMOR NECROSIS FACTOR RELATED PROTEIN 1; COMPLEMENT COMPONENT C1Q TUMOR NECROSIS FACTOR RELATED PROTEIN 12; COMPLEMENT COMPONENT C1Q TUMOR NECROSIS FACTOR RELATED PROTEIN 3; COMPLEMENT COMPONENT C1Q TUMOR NECROSIS FACTOR RELATED PROTEIN 9; GAMMA INTERFERON; GLUCOSE TRANSPORTER 4; INSULIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; RESISTIN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; THROMBOXANE B2; THROMBOXANE SYNTHASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; CYTOKINE;

ADIPOSE TISSUE; ADIPOSE TISSUE FIBROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENERGY EXPENDITURE; ENZYME DEFICIENCY; EXTRACELLULAR MATRIX; FATTY ACID BLOOD LEVEL; FIBROSIS; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; IN VITRO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; INTRAABDOMINAL FAT; LIMIT OF DETECTION; LIPID METABOLISM; LOW FAT DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SKELETAL MUSCLE; STROMA CELL; THROMBOXANE SYNTHASE DEFICIENCY; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WEIGHT GAIN; WHITE ADIPOSE TISSUE; 3T3 CELL LINE; ANIMAL; C57BL MOUSE; CELL CULTURE; DEFICIENCY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE MUTANT; PATHOLOGY;

3T3-L1 CELLS; ADIPOSE TISSUE; ANIMALS; CELLS, CULTURED; CYTOKINES; FEMALE; FIBROSIS; GENE EXPRESSION REGULATION; INFLAMMATION MEDIATORS; INSULIN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; THROMBOXANE-A SYNTHASE;

EID: 84929670128     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00383.2014     Document Type: Article

References (68)

1. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos- Flier E, Flier JS. Role of leptin in the neuroendocrine response to fasting. Nature 382: 250–252, 1996.
2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539–553, 1998.
3. Audoly LP, Rocca B, Fabre JE, Koller BH, Thomas D, Loeb AL, Coffman TM, FitzGerald GA. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 101: 2833–2840, 2000.
4. Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, Ciabattoni G, Patrono C, Davi G. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 48: 2531–2538, 2006.
5. Behm DJ, Ogbonna A, Wu C, Burns-Kurtis CL, Douglas SA. Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation. J Pharmacol Exp Ther 328: 231–239, 2009.
6. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs—differences and similarities. N Engl J Med 324: 1716–1725, 1991.
7. Brune K, Glatt M, Kalin H, Peskar BA. Pharmacological control of prostaglandin and thromboxane release from macrophages. Nature 274: 261–263, 1978.
8. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327: 70–75, 1992.
9. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 288: 2008–2014, 2002.
10. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56: 1655–1661, 2007.
11. Diczfalusy U, Falardeau P, Hammarstrom S. Conversion of prostaglandin endoperoxides to C17-hydroxy acids catalyzed by human platelet thromboxane synthase. FEBS Lett 84: 271–274, 1977.
12. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 12: 1063–1073, 1998.
13. Fitzgerald DJ, Rocki W, Murray R, Mayo G, FitzGerald GA. Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet 335: 751–754, 1990.
14. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83: 803–812, 1995.
15. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871–1875, 2001.
16. Ghoshal S, Trivedi DB, Graf GA, Loftin CD. Cyclooxygenase-2 deficiency attenuates adipose tissue differentiation and inflammation in mice. J Biol Chem 286: 889–898, 2011.
17. Gluais P, Lonchampt M, Morrow JD, Vanhoutte PM, Feletou M. Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. Br J Pharmacol 146: 834–845, 2005.
18. Graziani F, Biasucci LM, Cialdella P, Liuzzo G, Giubilato S, Della Bona R, Pulcinelli FM, Iaconelli A, Mingrone G, Crea F. Thromboxane production in morbidly obese subjects. Am J Cardiol 107: 1656–1661, 2011.
19. Halberg N, Khan T, Trujillo ME, Wernstedt-Asterholm I, Attie AD, Sherwani S, Wang ZV, Landskroner-Eiger S, Dineen S, Magalang UJ, Brekken RA, Scherer PE. Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 29: 4467–4483, 2009.
20. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72: 2994–2998, 1975.
21. Harman-Boehm I, Bluher M, Redel H, Sion-Vardy N, Ovadia S, Avinoach E, Shai I, Kloting N, Stumvoll M, Bashan N, Rudich A. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J Clin Endocrinol Metab 92: 2240–2247, 2007.
22. Haurand M, Ullrich V. Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme. J Biol Chem 260: 15059–15067, 1985.
23. Higgs GA, Moncada S, Salmon JA, Seager K. The source of thromboxane and prostaglandins in experimental inflammation. Br J Pharmacol 79: 863–868, 1983.
24. Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, Narumiya S. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 349: 617–620, 1991.
25. Hotamisligil GS. Inflammation and metabolic disorders. Nature 444: 860–867, 2006.
26. Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, Zhang BB, Bonaldo P, Chua S, Scherer PE. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 29: 1575–1591, 2009.
27. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK, Katagiri H, Majima M, Yokode M, Kita T, Narumiya S. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114: 784–794, 2004.
28. Lewis RA, Austen KF. The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest 73: 889–897, 1984.
29. Li P, Lu M, Nguyen MT, Bae EJ, Chapman J, Feng D, Hawkins M, Pessin JE, Sears DD, Nguyen AK, Amidi A, Watkins SM, Nguyen U, Olefsky JM. Functional heterogeneity of CD11c-positive adipose tissue macrophages in diet-induced obese mice. J Biol Chem 285: 15333–15345, 2010.
30. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117: 175–184, 2007.
31. Mehta JL, Lawson D, Mehta P, Saldeen T. Increased prostacyclin and thromboxane A2 biosynthesis in atherosclerosis. Proc Natl Acad Sci USA 85: 4511–4515, 1988.
32. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11: 723–737, 2011.
33. Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 261: 558–560, 1976.
34. Odegaard JI, Chawla A. Alternative macrophage activation and metabolism. Annu Rev Pathol 6: 275–297, 2011.
35. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Red Eagle A, Vats D, Brombacher F, Ferrante AW, Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447: 1116– 1120, 2007.
36. Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med 357: 1841–1854, 2007.
37. Peterson JM, Aja S, Wei Z, Wong GW. C1q/TNF-related protein-1 (CTRP1) enhances fatty acid oxidation via AMPK activation and ACC inhibition. J Biol Chem 287: 1576–1587, 2012.
38. Peterson JM, Seldin MM, Wei Z, Aja S, Wong GW. CTRP3 attenuates diet-induced hepatic steatosis by regulating triglyceride metabolism. Am J Physiol Gastrointest Liver Physiol 305: G214–G224, 2013.
39. Peterson JM, Wei Z, Seldin MM, Byerly MS, Aja S, Wong GW. CTRP9 transgenic mice are protected from diet-induced obesity and metabolic dysfunction. Am J Physiol Regul Integr Comp Physiol 305: R522–R533, 2013.
40. Peterson JM, Wei Z, Wong GW. C1q/TNF-related protein-3 (CTRP3), a novel adipokine that regulates hepatic glucose output. J Biol Chem 285: 39691–39701, 2010.
41. Pulcinelli FM, Biasucci LM, Riondino S, Giubilato S, Leo A, Di Renzo L, Trifiro E, Mattiello T, Pitocco D, Liuzzo G, Ghirlanda G, Crea F. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J 30: 1279–1286, 2009.
42. Remuzzi G, Imberti L, Rossini M, Morelli C, Carminati C, Cattaneo GM, Bertani T. Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis. J Clin Invest 75: 94–101, 1985.
43. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31: 986–1000, 2011.
44. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973–979, 1997.
45. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 444: 847–853, 2006.
46. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 72: 3073–3076, 1975.
47. Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Hammarstrom S, Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem 47: 997–1029, 1978.
48. Saraswathi V, Ramnanan CJ, Wilks AW, Desouza CV, Eller AA, Murali G, Ramalingam R, Milne GL, Coate KC, Edgerton DS. Impact of hematopoietic cyclooxygenase-1 deficiency on obesity-linked adipose tissue inflammation and metabolic disorders in mice. Metabolism 62: 1673–1685, 2013.
49. Shen RF, Tai HH. Immunoaffinity purification and characterization of thromboxane synthase from porcine lung. J Biol Chem 261: 11592–11599, 1986.
50. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145–182, 2000.
51. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J Lipid Res 50, Suppl: S423–S428, 2009.
52. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest 121: 2094–2101, 2011.
53. Sun K, Tordjman J, Clement K, Scherer PE. Fibrosis and adipose tissue dysfunction. Cell Metab 18: 470–477, 2013.
54. Thomas DW, Mannon RB, Mannon PJ, Latour A, Oliver JA, Hoffman M, Smithies O, Koller BH, Coffman TM. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest 102: 1994–2001, 1998.
55. Thomas DW, Rocha PN, Nataraj C, Robinson LA, Spurney RF, Koller BH, Coffman TM. Proinflammatory actions of thromboxane receptors to enhance cellular immune responses. J Immunol 171: 6389–6395, 2003.
56. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 108: 15–23, 2001.
57. Tripp CS, Leahy KM, Needleman P. Thromboxane synthase is preferentially conserved in activated mouse peritoneal macrophages. J Clin Invest 76: 898–901, 1985.
58. Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 1801: 209–214, 2010.
59. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232–235, 1971.
60. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97–120, 1998.
61. Wei Z, Lei X, Petersen PS, Aja S, Wong GW. Targeted deletion of C1q/TNF-related protein 9 increases food intake, decreases insulin sensitivity, and promotes hepatic steatosis in mice. Am J Physiol Endocrinol Metab 306: E779–E790, 2014.
62. Wei Z, Peterson JM, Lei X, Cebotaru L, Wolfgang MJ, Baldeviano GC, Wong GW. C1q/TNF-related protein-12 (CTRP12), a novel adipokine that improves insulin sensitivity and glycemic control in mouse models of obesity and diabetes. J Biol Chem 287: 10301–10315, 2012.
63. Wei Z, Seldin MM, Natarajan N, Djemal DC, Peterson JM, Wong GW. C1q/tumor necrosis factor-related protein 11 (CTRP11), a novel adipose stroma-derived regulator of adipogenesis. J Biol Chem 288: 10214–10229, 2013.
64. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796–1808, 2003.
65. Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Revett T, Gimeno R, Lodish HF. Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J 416: 161–177, 2008.
66. Wong GW, Wang J, Hug C, Tsao TS, Lodish HF. A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci USA 101: 10302–10307, 2004.
67. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821–1830, 2003.
68. Yu IS, Lin SR, Huang CC, Tseng HY, Huang PH, Shi GY, Wu HL, Tang CL, Chu PH, Wang LH, Wu KK, Lin SW. TXAS-deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death. Blood 104: 135–142, 2004.